Found 56 clinical trials
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
Family Medicine
-
Currently Recruiting
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lymphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)
(MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these
- 88 views
- 15 Apr, 2019
- 1 location
-
Multi-country trial
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Immunology
-
Currently Recruiting
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
- 92 views
- 13 Dec, 2020
- 29 locations
-
Multi-country trial
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Immunology
-
Currently Recruiting
An Open-label Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage 1) and a dose expansion stage (Stage 2).
- 0 views
- 23 Jan, 2021
- 10 locations
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Hematology
-
Currently Recruiting
Dasatinib In Waldenstr m Macroglobulinemia
This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenstrm Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK
- 2 views
- 30 Dec, 2020
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
Hypothesis; That inhibition of plasma Blys by the monoclonal antibody Belimumab will reduce both the survival of the lymphoplasmacytoid cells of Waldenstrom Macroglobulinaemia (WM), and
- 8 views
- 08 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia
A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenstrm's macroglobulinemia
- 0 views
- 01 Oct, 2020
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
Zanubrutinib Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID regimen will
- 0 views
- 24 Jan, 2021
- 1 location
-
Phase 4 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Hematology
-
Currently Recruiting
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
Response Criteria from the Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) (NCCN 2019), in Chinese participants with relapsed or refractory waldenstrom's macroglobulinemia.
- 1 views
- 17 Dec, 2020
- 11 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R WM will be evaluated in approximately 44 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.
- 0 views
- 24 Jan, 2021
- 16 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Hematology
-
Currently Recruiting
Daratumumab Plus Ibrutinib in Patients With Waldenstr m's Macroglobulinemia
This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with Waldenstrm's macroglobulinemia (WM). The study will evaluate this combination in two
- 1 views
- 01 Jan, 2021
- 1 location